跳至主要内容
临床试验/KCT0004925
KCT0004925
尚未招募
未知

A 12 week, randomized, double-blind, placebo-controlled clinical trial for the evaluation of the efficacy and safety of HT083 on mild Osteoarthritis

The Catholic University of Korea, Uijeongbu St. Mary’s Hospital0 个研究点目标入组 100 人待定

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
未指定
发起方
The Catholic University of Korea, Uijeongbu St. Mary’s Hospital
入组人数
100
状态
尚未招募
最后更新
6年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
待定
结束日期
待定
最后更新
6年前
研究类型
Interventional Study
性别
All

研究者

发起方
The Catholic University of Korea, Uijeongbu St. Mary’s Hospital

入排标准

入选标准

  • 1\)Male or female adults aged between 35 and 70 years of age.
  • 2\)Subjects with a visual analog scale (VAS) score of more than 30 mm
  • 3\)Subjects with Kellgren and Lawrence grade I or II determined by X\-ray
  • 4\)Subjects who agree to participate in the clinical trial voluntarily and sign the informed consent form (ICF)

排除标准

  • 1\)A person who has arthritis other than osteoarthritis.
  • 2\)A person whose joint space is less than 2 mm.
  • 3\)A person with moderate osteoarthritis accompanied by osteoporosis, irregular joint surface, subchondral osteocytes of the joint and so on.
  • 4\)Those who have clinically significant cardiovascular, autoimmune, infectious or neoplastic diseases in addition to joint pain.
  • 5\)Hypertension patients with more than 160mmHg systolic blood pressure or more than 100mmHg diastolic blood pressure.
  • 6\)Diabetic patients whose fasting blood glucose level is above 180 mg / dl).
  • 7\)TSH lower than 0\.1µIU/ml or upper than 10 µIU/ml
  • 8\)A person who has AST (GOT) or ALT (GPT) level 3 times higher than the normal upper limit.
  • 9\)Abnormal creatinine level (more than twice the normal upper limit).
  • 10\)Those who have taken arthritis medicines or dietary supplements for joint health within 2 weeks of visit.

结局指标

主要结局

未指定

相似试验